Acutaas Chemicals Ltd

- No explicit mention of any new fundraising through debt or equity at present or in the near future. - The company has recently completed a QIP (Qualified Institutional Placement) raising around Rs. 500 crore, used mainly for debt repayment (~Rs. 250 crore) and CAPEX. - Current cash and cash equivalents stand at Rs. 279 crore. - No mention of plans for further QIP or debt raising during FY25 or FY26. - CAPEX guidance for FY25 is Rs. 250 crore and FY26 is Rs. 40 crore, expected to be funded through internal accruals and existing resources. - Management highlighted cautious investment approach, especially regarding the EV-related JV, waiting for clear visibility before committing funds.

- FY25 CAPEX for AMI Organics is around ₹250 crore, including: - ₹70 crore for Unit 2 Ankleshwar site (expected completion Q3 FY25) - ₹100 crore for electrolyte additive project (capacity 2000 MT for VC and FEC, completion expected by Q1 FY26) - ₹60 crore for captive solar power plant (completion expected by end Q3 FY25) - ₹30 crore for regular maintenance CAPEX - FY26 CAPEX is expected to be around ₹40 crore primarily for maintenance. - Strategic investments include: - Expansion of Ankleshwar unit capacity to 442 KL in three blocks, fully operational over three years. - Electrolyte additive capacity build-up following long-term contracts. - Careful evaluation and cautious investment in EV-related projects due to deferrals in the EV market. - Potential joint venture with Enchem under discussion, status quo currently. - ₹88 crore from QIP reserved for general corporate purposes and future opportunities.

- AMI Organics targets a 30% revenue growth for FY25, revised upward from 25%, driven by strong order book and forecast. - The company expects a consistent ~25% CAGR growth in the medium term based on a robust product pipeline and existing CDMO contracts. - CDMO business to scale up materially from Q3 FY25 onwards, providing sizable additional revenue. - Ankleshwar unit at full utilization is expected to generate around ₹900 crore revenue, with 310 crore CAPEX invested. - The ramp-up for the Fermion contract and CDMO projects will continue through FY25, with full capacity utilization expected by FY26. - Specialty Chemicals (excluding Baba Fine Chem) is growing over 25%, and pharma intermediates grew 53% Y-o-Y in Q2 FY25. - New geographic expansions (e.g., Korea, Japan) and product launches support growth beyond FY25. - EBITDA margins expected to improve on operational leverage and stabilized pricing through FY25-FY26.

- AMI Organics targets a revenue CAGR of approximately 25% annually, supported by a strong product pipeline extending to 2045. - FY25 growth guidance is revised to 30%, considered conservative by management. - Margins are expected to improve steadily, with a goal to exceed 25%-30% EBITDA margin within the next three years (versus current ~20%). - CDMO segment expected to show significant growth from next quarter onwards, contributing to margin expansion. - The Fermion contract and other CDMO projects in advanced stages will contribute to sizable revenue growth in coming years. - CAPEX investments (Rs. 250 crore in FY25) and new Ankleshwar unit ramp-up will enable scaling and higher profitability. - Long-term visibility driven by ongoing contracts with originators and generic players. - Deferral in EV battery investments may delay related growth, but overall demand recovery anticipated from FY26 onwards.

- The management mentioned that the 30% top-line growth guidance for FY25 is based on forecast and orders currently on hand, indicating a healthy order book supporting this growth. - CDMO project ramp-up is still underway with full effect expected beyond Q2 FY25. - For the Fermion contract, sales are ramping up gradually with full utilization expected by FY26, covering multiple regulated markets. - New contracts with originator clients in Europe are near completion, expected to result in supplies starting Q4 FY25 or Q1 FY26. - Validation batches for electrolyte additives have been supplied; commercial orders depend on customer approvals and may start as early as Q3 or Q4 FY25. - Overall, a strong product pipeline with multiple phase II and III drug intermediates in the pipeline supports growth visibility. - Ankleshwar unit expected to be fully operational by Q4 FY25, with 3x revenue potential over CAPEX indicating robust future order traction.